Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Bay 3713372

Preclinical

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

MTAP-Deleted Solid TumorsRecruiting

MTAP-Deleted Solid TumorsPreclinical

Recruiting

Timeline

Expected Milestones

Q2 2029

PreclinicalRecruiting

MTAP-Deleted Solid Tumors

NCT06914128

Clinical

Trials by Indication[1]

MTAP-deleted Solid Tumors1 trial

A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of BAY 3713372, a Novel 2nd Generation PRMT5 Inhibitor, in Participants With MTAP-deleted Solid Tumors.

Recruiting· Bayer logo

Bayer·Preclinical·NCT06914128·450 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Bay 3713372. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Bay 3713372. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: Bayer

Related News